Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Pediatric Solid Tumors

Trial Profile

Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Pediatric Solid Tumors

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Thalidomide (Primary)
  • Indications Ependymoma; Ewing's sarcoma; Glioma; Medulloblastoma; Neuroectodermal tumours; Osteosarcoma; Retinoblastoma; Rhabdomyosarcoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Nov 2016 Planned End Date changed from 1 Feb 2020 to 1 Feb 2021.
    • 29 Jul 2013 Planned number of patients changed from 18 to 12 as reported by ClinicalTrials.gov.
    • 29 Jul 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top